Pooled Mutant KRAS-Targeted Long Peptide Vaccine Combined With Nivolumab and Ipilimumab for Patients With Resected Mismatch Repair Protein (MMR-p) Colorectal and Pancreatic Cancer

Johns Hopkins Medicine logo

Johns Hopkins Medicine

Status and phase

Phase 1


Pancreatic Cancer
Colorectal Cancer


Drug: KRAS peptide vaccine
Drug: Nivolumab
Drug: Ipilimumab

Study type


Funder types



5P01CA247886 (Other Identifier)
IRB00210915 (Other Identifier)
K08CA248624 (U.S. NIH Grant/Contract)

Details and patient eligibility


Phase 1 study for patients with resected PDAC after neoadjuvant and/ or adjuvant chemotherapy and/or radiation, as well as patients with metastatic colorectal cancer who have exposure to 2 or more lines of chemotherapy, to evaluate safety and the immune response to pooled mutant-KRAS peptide vaccine (KRAS peptide vaccine) with poly-ICLC adjuvant in combination with nivolumab and ipilimumab.


30 estimated patients




18+ years old


No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:

PDAC or metastatic MSS CRC Cohort:

Have histologically or cytologically - proven cancer of the pancreas (PDA) or MSS colorectal (CRC) in one of the following categories:

  • PDAC must have no evidence of disease and last dose of neoadjuvant and/or adjuvant chemotherapy/radiation therapy/or surgery must be < 6 months from study entry.
  • Metastatic MSS CRC after exposure to 2 more lines of chemotherapy in the metastatic setting including 5-flurouracil, irinotecan, and oxaliplatin exposure. Patients treated with FOLFOXIRI may enroll after progression or intolerance to that regimen.
  • For metastatic MSS CRC cohort, must have tumor lesions amenable to repeated biopsy, and patient's acceptance to have a tumor biopsy of an accessible lesion at baseline and on treatment if the lesion can be biopsied with acceptable clinical risk (as judged by the Principal Investigator).
  • For metastatic MSS CRC patients, must have measurable disease per RECIST 1.1.

Reinduction Treatment Cohort:

  • Have a single site of locoregional recurrence or distant metastasis noted on imaging > 12 months after the first dose of the mutant KRAS peptide vaccine with poly-ICLC adjuvant.
  • Have completed definitive treatment for solitary recurrence per standard-of-care (e.g. surgical resection, radiation, and/or chemotherapy) <6 months prior to screening for reinduction treatment.

Both Cohorts:

*Age ≥18 years.

  • Have sufficient archival tumor tissue for next-generation sequencing (NGS) and immune-phenotyping.
  • Have one of the KRAS mutations included in the vaccine at the time of vaccination expressed in tumor.
  • Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1
  • Life expectancy of greater than 6 months.
  • Patients must have adequate organ and marrow function defined by study-specified laboratory tests prior to initial study drug.
  • Woman of childbearing potential must have a negative pregnancy test and follow contraceptive guidelines as defined per protocol.
  • Men must use acceptable form of birth control while on study.
  • Ability to understand and willingness to sign a written informed consent document.

Exclusion Criteria

If expected to require any other form of systemic or localized antineoplastic therapy while on study.

Within 2 weeks prior to first dose of study drug.

  • Systemic or topical steroids corticosteroids at immunosuppressive doses (> 10 mg/day of prednisone or equivalent). Inhaled or topical steroids, and adrenal replacement steroid doses ≤ 10 mg daily prednisone equivalent, are permitted in the absence of active autoimmune disease.
  • Any palliative or adjuvant radiation or gamma knife radiosurgery.
  • Any chemotherapy.

Within 4 weeks prior to first dose of study drug.

  • Any investigational cytotoxic drug.
  • Any investigational device.
  • Has received a live vaccine.
  • Received any allergen hyposensitization therapy.
  • Received any growth factors, e.g. granulocyte-colony stimulating factor (G-CSF), granulocyte macrophage-colony stimulating factor (GM-CSF), erythropoietin.
  • Any major surgery.
  • PDAC or metastatic MSS CRC Cohort: Prior treatment with immunotherapy agents (including, anti-PD-1, anti-PD-L1, anti-PD-L2, anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA4), etc.).
  • Hypersensitivity reaction to any monoclonal antibody.
  • Known history or evidence of brain metastases.
  • Has active autoimmune disease that has required systemic treatment in the past 2 years, or a documented history of clinically severe autoimmune disease, or a syndrome that requires systemic steroids or immunosuppressive agents.
  • Known history or concurrent interstitial lung disease.
  • Has a pulse oximetry < 92% on room air.
  • Requires the use of home oxygen.
  • Infection with HIV or hepatitis B or C.
  • Uncontrolled intercurrent illness including, but not limited to, uncontrolled infection, symptomatic congestive heart failure, unstable angina, cardiac arrhythmia, metastatic cancer, or psychiatric illness/social situations that would limit compliance with study requirements.
  • Has been diagnosed with another cancer or myeloproliferative disorder within the past 5 year.
  • Has a diagnosis of immunodeficiency.
  • Presence of any tissue or organ allograft, regardless of need for immunosuppression, including corneal allograft. Patients with a history of allogeneic hematopoietic stem cell transplant will be excluded.
  • Any other sound medical, psychiatric, and/or social reason as determined by the Investigator.
  • Unwilling or unable to follow the study schedule for any reason.
  • Are pregnant or breastfeeding.
  • For metastatic MSS CRC and Reinduction Treatment Cohorts, any peritoneal involvement by the tumor.
  • For metastatic MSS CRC and Reinduction Treatment Cohorts, any radiological or clinical pleural effusions or ascites.
  • For metastatic MSS CRC and Reinduction Treatment Cohorts, patients on parenteral nutrition.
  • For metastatic MSS CRC and Reinduction Treatment Cohorts, patients with any single liver metastases greater than 5 cm or greater > 50% liver involvement.
  • For metastatic MSS CRC and Reinduction Treatment Cohorts, history of malignant bowel obstruction.

Trial design

Primary purpose




Interventional model

Parallel Assignment


None (Open label)

30 participants in 2 patient groups

Treatment Phase
Experimental group
KRAS Vaccine Peptide, Nivolumab and Ipilimumab
Drug: Ipilimumab
Drug: Nivolumab
Drug: KRAS peptide vaccine
Reinduction Treatment Phase
Experimental group
KRAS Vaccine Peptide, Nivolumab and Ipilimumab
Drug: Ipilimumab
Drug: Nivolumab
Drug: KRAS peptide vaccine

Trial contacts and locations



Central trial contact

Colleen Apostol, RN; Joann Santmyer, RN

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems